Hyperimmune globulin for severely immunocompromised patients hospitalized with coronavirus disease 2019: a randomized, controlled trial
S Huygens, Q Hofsink, IS Nijhof… - The Journal of …, 2023 - academic.oup.com
S Huygens, Q Hofsink, IS Nijhof, A Goorhuis, AP Kater, PA Te Boekhorst, F Swaneveld…
The Journal of infectious diseases, 2023•academic.oup.comBackground The aim of this randomized, controlled trial is to determine whether antisevere
acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against
severe coronavirus disease 2019 (COVID-19) in severely immunocompromised,
hospitalized, COVID-19 patients. Methods Patients were randomly assigned to receive
COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Results
Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 …
acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against
severe coronavirus disease 2019 (COVID-19) in severely immunocompromised,
hospitalized, COVID-19 patients. Methods Patients were randomly assigned to receive
COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Results
Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 …
Background
The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients.
Methods
Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies.
Results
Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher’s exact test).
Conclusions
Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.
Oxford University Press